# Panic Disorder

Evaluate acute cardiopulmonary, respiratory, toxicologic, and substance-related mimics before diagnosing panic disorder. Confirm recurrent unexpected attacks plus persistent concern or avoidance, then select disorder-focused CBT, an SSRI or SNRI, or both according to severity, preference, access, and comorbidity.

**Clinical question:** How should clinicians exclude dangerous mimics, confirm panic disorder, and choose evidence-supported treatment?

Updated: 2026-09-15T17:20:25.610991+00:00

## What matters in practice
- In acute presentations, assess cardiopulmonary and respiratory causes and drug exposure before assigning panic disorder; point-of-care lung ultrasonography, chest radiography, peak flowmetry, and toxicology screening are specifically described emergency tests. [23]
- Panic disorder requires recurrent unexpected panic attacks plus at least 1 month of persistent attack-related concern, worry, or maladaptive behavioral change; agoraphobia is diagnostically distinct. [24]
- Use a structured severity measure such as the Panic Disorder Severity Scale to establish baseline burden and monitor response. [23]
- CBT has sustained benefit versus control conditions for panic disorder at 1 to 6 months and 6 to 12 months after treatment completion. [4]
- Guidelines reviewed across anxiety disorders identify SSRIs or SNRIs as first-line pharmacotherapy; benzodiazepines, TCAs, and other agents are not first-line choices. [13]

## Do not diagnose panic disorder before excluding acute medical illness

Stabilize and investigate according to the presenting symptom complex rather than attributing chest pain or dyspnea to anxiety.

For an acute episode with chest discomfort, dyspnea, wheeze, syncope, or marked autonomic symptoms, perform a focused cardiopulmonary and substance-exposure assessment before making a psychiatric diagnosis. Emergency evaluation may include point-of-care lung ultrasonography, bedside chest radiography, and peak flowmetry to identify respiratory abnormalities; obtain toxicology screening when drug misuse or intoxication is plausible. [23]

A panic attack has abrupt onset, peaks within 10 minutes, and is characterized by at least 4 physical or cognitive symptoms; an episode commonly lasts about 1 hour. This temporal pattern supports, but does not establish, a panic diagnosis because acute medical disorders can present with similar symptoms. [23]

After acute physical causes have been evaluated, document the event phenotype, triggers, frequency, avoidance, current medications, and substance use. A symptom score can quantify burden but cannot replace medical exclusion or longitudinal diagnostic assessment. [23]
- Use bedside lung ultrasonography, chest radiography, and peak flowmetry when respiratory pathology is in the acute differential. [23]
- Order toxicology screening when stimulant, other substance, or medication-related symptoms are possible. [23]
- Do not use a brief emergency presentation alone to establish the longitudinal persistence criterion for panic disorder. [23][24]

*Acute branches that determine the next diagnostic action. [23]*

| Presentation pattern | Immediate diagnostic action | Interpretation and next step |
| --- | --- | --- |
| Dyspnea, wheeze, or suspected respiratory abnormality | Point-of-care lung ultrasonography, bedside chest radiography, and peak flowmetry. [23] | Treat or further evaluate identified respiratory disease; diagnose panic disorder only after physical causes are addressed. [23] |
| Symptoms with possible substance exposure | Toxicology screening. [23] | If exposure is identified, assess a substance- or medication-related cause before assigning primary panic disorder. [23] |
| Abrupt fear with autonomic and cognitive symptoms | Characterize onset, peak, symptom count, recurrence, and post-attack behavior. [23][24] | Rapid peak supports a panic attack phenotype; recurrent unexpected attacks plus persistent sequelae are required for panic disorder. [23][24] |

## Confirm panic disorder and separate agoraphobic avoidance

The diagnostic pivot is recurrence of unexpected attacks followed by durable concern or behavior change.

Diagnose panic disorder when recurrent unexpected panic attacks are accompanied by at least 1 month of persistent concern, worry, or behavioral change related to attacks. The post-attack persistence requirement distinguishes a recurrent disorder from an isolated panic attack. [24]

Assess agoraphobia separately. DSM-5 distinguishes agoraphobia from panic disorder, so document avoidance and its functional effect rather than treating agoraphobic behavior as automatically establishing panic disorder. [24]

Measure baseline severity with the Panic Disorder Severity Scale, Panic Disorder Self-Report, Panic and Agoraphobia Scale, NIMH Panic Questionnaire, or Panic-Associated Symptoms Scale. The Panic Disorder Severity Scale is among tools identified for physician use in emergency and primary-care settings. [23]
- Record whether attacks are unexpected versus situationally cued; the disorder criterion specifies recurrent unexpected attacks. [24]
- Ask whether attack-related concern, catastrophic worry, or avoidance has persisted for at least 1 month. [24]
- Document agoraphobia as a separate diagnostic and treatment target. [24]

*Diagnostic elements that change classification and management. [23][24]*

| Finding | Clinical interpretation | Action |
| --- | --- | --- |
| Single or recurrent episodes without documented 1-month sequelae | A panic attack phenotype may be present, but the persistence criterion for panic disorder is not established. [23][24] | Continue medical and longitudinal assessment; avoid prematurely labeling panic disorder. [24] |
| Recurrent unexpected attacks plus ≥1 month of worry, concern, or behavioral change | Meets the operational DSM-5 description of panic disorder. [24] | Establish severity baseline and initiate disorder-focused treatment. [23][24] |
| Avoidance consistent with agoraphobia | Agoraphobia is distinguished from panic disorder in DSM-5. [24] | Document separately and incorporate avoidance-focused treatment goals. [24] |

## Choose CBT, first-line antidepressant therapy, or both

Select treatment by patient preference, access, symptom burden, avoidance, comorbidity, and prior treatment response.

Offer cognitive behavioral therapy as an evidence-based treatment pathway. In a systematic review and meta-analysis of 69 randomized trials involving 4,118 outpatients with anxiety-related disorders, CBT was associated with better panic-disorder outcomes than control conditions after treatment and at 1 to 6 months and 6 to 12 months of follow-up; reported Hedges g values for panic disorder were 0.22 to 0.35. [4]

When medication is chosen, use an SSRI or SNRI as first-line pharmacotherapy. An umbrella review of antipsychotic agents in anxiety disorders reports that treatment guidelines recommend SSRIs or SNRIs first line, whereas benzodiazepines, TCAs, and other agents are not first-line pharmacotherapy. [13]

For patients preferring psychodynamic treatment or unable to engage in CBT, panic-focused psychodynamic psychotherapy has randomized-trial evidence versus applied relaxation training, but its comparative effectiveness against CBT and medications remains unresolved. [6] Do not substitute an untested modality for CBT or a first-line antidepressant without clarifying that evidence limitation.
- Use CBT when the patient prefers psychotherapy, has prominent avoidance, or wants a nonpharmacologic first-line option; outcomes remained superior to control conditions through 12 months after completion. [4]
- Use an SSRI or SNRI when pharmacotherapy is preferred or indicated by clinical context; reassess tolerability and response rather than escalating to non-first-line classes by default. [13]
- Consider panic-focused psychodynamic psychotherapy as an alternative psychotherapy option, while counseling that direct comparisons with CBT and medications are needed. [6]

### Avoid reflexive antipsychotic use

Do not use an antipsychotic as routine first-line pharmacotherapy for panic disorder. Guideline recommendations summarized in an umbrella review place SSRIs and SNRIs first line and classify benzodiazepines, TCAs, and other agents outside that first-line position. [13]

*Treatment-selection framework for confirmed panic disorder. [4][6][13]*

| Clinical situation | Preferred next step | Key tradeoff |
| --- | --- | --- |
| Patient prefers psychotherapy or has a strong avoidance target | Offer CBT. [4] | CBT showed benefit versus control conditions through 6 to 12 months after treatment completion. [4] |
| Patient prefers medication or requires pharmacotherapy | Start an SSRI or SNRI as first-line pharmacotherapy. [13] | Monitor response and tolerability before moving to non-first-line medication classes. [13] |
| CBT is unavailable, unacceptable, or not feasible | Discuss panic-focused psychodynamic psychotherapy as an alternative. [6] | Evidence exists versus applied relaxation training, but comparative evidence against CBT and medications is still needed. [6] |
| Considering antipsychotic, benzodiazepine, or TCA as initial treatment | Reassess the treatment plan; these are not identified as first-line pharmacotherapy in guideline summaries. [13] | Reserve non-first-line approaches for individualized circumstances rather than routine initial management. [13] |

## Measure response and reassess the diagnosis before changing treatment

Track attack burden, anticipatory anxiety, avoidance, function, adverse effects, adherence, and alternative explanations at each treatment decision.

Use the same structured measure at baseline and follow-up when possible, particularly the Panic Disorder Severity Scale or a panic-specific self-report instrument. This makes change in panic frequency, symptom burden, and agoraphobic avoidance visible rather than relying solely on an unstructured global impression. [23]

When response is inadequate, first reassess adherence, diagnostic accuracy, and comorbidities before changing therapy. Across adult depression guidelines, this sequence was a common initial recommendation for inadequate first-line treatment and is a useful safeguard against premature medication switching in patients with persistent panic-like symptoms. [3]

Reopen the medical differential when the symptom pattern changes, new cardiopulmonary or respiratory findings emerge, or substance exposure becomes plausible. Repeat targeted evaluation rather than attributing all subsequent episodes to a prior panic diagnosis. [23]
- At each visit, record panic frequency, attack-related worry, avoidance, function, treatment adherence, and adverse effects using a consistent instrument. [23]
- Before declaring treatment failure, reassess diagnosis, adherence, and comorbid conditions. [3]
- Escalate or repeat medical evaluation for a changed acute phenotype rather than assuming recurrence of panic disorder. [23]

*Follow-up decisions after treatment initiation. [3][23]*

| Follow-up finding | Next action | Reason |
| --- | --- | --- |
| Improvement on baseline panic measure | Continue the effective treatment plan and continue structured symptom monitoring. [23] | A panic-specific tool provides a reproducible measure of change. [23] |
| Persistent symptoms with uncertain adherence, diagnosis, or comorbidity | Assess adherence, reassess diagnosis, and evaluate comorbidities before changing first-line treatment. [3] | These were common first steps across reviewed inadequate-response guidelines. [3] |
| New or changed dyspnea, chest, respiratory, or substance-related features | Repeat targeted acute medical evaluation, including respiratory testing or toxicology screening when indicated. [23] | Physical and substance-related causes require reassessment before psychiatric attribution. [23] |

## References
1. [PDF] NDA 215455 - FDA — www.fda.gov — https://www.fda.gov/media/178984/download
2. [PDF] Prozac (fluoxetine hydrochloride) 10 mg, 20 ... - accessdata.fda.gov — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/021235Orig1s016.pdf
3. Quality of clinical practice guidelines for inadequate response to first-line treatment for depression according to AGREE II checklist and comparison of recommendations: a systematic review | BMJ Open — bmjopen.bmj.com — https://bmjopen.bmj.com/content/12/4/e051918
4. Long-term Outcomes of Cognitive Behavioral Therapy for Anxiety-Related Disorders: A Systematic Review and — jamanetwork.com — https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2756136
5. Which psychotherapy is effective in panic disorder? And which delivery formats are supported by the evidence? Study protocol for two systematic reviews and network meta-analyses — bmjopen.bmj.com — https://bmjopen.bmj.com/content/10/12/e038909
6. Psychodynamic Psychotherapy for Panic Disorder? | NEJM Clinician — clinician.nejm.org — https://clinician.nejm.org/psychodynamic-psychotherapy-panic-disorder-JP200703120000001
7. Screening for Anxiety in Adolescent and Adult Women - ACP Journals — www.acpjournals.org — https://www.acpjournals.org/doi/10.7326/M20-0579
8. Management of Chronic Insomnia Disorder in Adults - ACP Journals — www.acpjournals.org — https://www.acpjournals.org/doi/10.7326/M15-2175
9. The quality and clinical applicability of recommendations in anxiety disorders guidelines: A systematic review of seventeen guidelines from seven countries - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0165032721009083
10. Couple therapy and systemic interventions for adult‐focused ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/1467-6427.12481
11. Panic Disorder and Migraine: Comorbidity, Mechanisms, and ... — headachejournal.onlinelibrary.wiley.com — https://headachejournal.onlinelibrary.wiley.com/doi/10.1111/head.12004
12. The identification and psychological treatment of panic disorder in ... — acamh.onlinelibrary.wiley.com — https://acamh.onlinelibrary.wiley.com/doi/pdf/10.1111/camh.12372
13. Antipsychotic agents in anxiety disorders: An umbrella review — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1111/acps.13669
14. A Network Analysis of Panic Disorder, Agoraphobia, and ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1002/brb3.71241
15. Evaluating the efficacy of psychological therapies for generalised ... — acamh.onlinelibrary.wiley.com — https://acamh.onlinelibrary.wiley.com/doi/10.1002/jcv2.70056
16. Diagnosis and treatment of patients with bipolar disorder — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/pdf/10.1002/2327-6924.12275
17. Cardiac Anxiety - an overview | ScienceDirect Topics — www.sciencedirect.com — https://www.sciencedirect.com/topics/neuroscience/cardiac-anxiety
18. A meta-analysis of the efficacy of psycho- and pharmacotherapy in panic disorder with and without agoraphobia - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0165032705001278
19. Table A4, Characteristics of Included Guidelines - Yoga for the Treatment of Post-Traumatic Stress Disorder, Generalized Anxiety Disorder, Depression, and Substance Abuse: A Review of the Clinical Effectiveness and Guidelines - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK304568/table/T5?report=objectonly
20. Table 1, Current clinical practice guidelines for the treatment of child and adolescent DDs - Treatment of Depression in Children and Adolescents: A Systematic Review - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK555846/table/ch2.tab1
21. Table 4, Characteristics of Included Guidelines - Short-Term Psychodynamic Psychotherapy for the Treatment of Mental Illness: A Review of Clinical Effectiveness and Guidelines - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK525874/table/app2.t3?report=objectonly
22. Clinical Guidelines on Long-Term Pharmacotherapy for Bipolar Disorder in Children and Adolescents - PMC — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449672?term=
23. Clinical Practice Guidelines for Assessment and Management of ... — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC10096212
24. Panic Disorder: Current Research and Management Approaches - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC6354045

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.